Preparation of 111In-DTPA morpholino oligomer for low abdominal accumulation

Applied Radiation and Isotopes

Volumn 68, Issue 9, 2010, Pages 1709-1714

  Liu, Guozheng ^a   Dou, Shuping ^a   Rusckowski, Mary ^a   Greiner, Dale ^a   Hnatowich, Donald ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Conjugation; DNA analog; Indium 111; Purification; Radiolabeling

Indexed keywords

AMMONIUM ACETATE; AVERAGE NUMBERS; BACKGROUND RADIOACTIVITY; BETA CELL; CARBODIIMIDE HYDROCHLORIDES; CONJUGATION; INDIUM-111; LOW MASS; MOLAR RATIO; NORMAL TISSUE; NUCLEAR IMAGING; RADIOLABEL; RADIOLABELING; SPECIFIC ACTIVITY; SPECIFIC RADIOACTIVITY; STERIC HINDRANCES; SULFONIC ACID; TARGET ORGANS; TRANSCHELATION; TRINITROBENZENE;

AMMONIUM COMPOUNDS; OLIGOMERS; ORGANIC COMPOUNDS; PURIFICATION; RADIATION; RADIOACTIVITY; TISSUE; VOLATILE FATTY ACIDS;

EFFICIENCY;

4 AMINOBUTYRIC ACID; AMMONIUM ACETATE; MORPHOLINE; MORPHOLINO OLIGONUCLEOTIDE; OLIGOMER; PENTETATE INDIUM IN 111; TECHNETIUM 99M; TRINITROBENZENESULFONIC ACID; DIAGNOSTIC AGENT; INDIUM; OLIGONUCLEOTIDE; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT;

ABDOMEN; ARTICLE; CHEMICAL STRUCTURE; CONJUGATION; ELUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PURIFICATION; RADIOACTIVITY; RADIOCHROMATOGRAPHY; ANIMAL; CHEMISTRY; HUMAN; METHODOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SYNTHESIS;

ABDOMEN; ANIMALS; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; OLIGONUCLEOTIDES; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79551684202     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2010.03.002     Document Type: Article

References (36)

1. Azegami M., Iwai K. Specific modification of nucleic acids and their constituents with trinitrophneyl group. J. Biochem. 1964, 55:346-348.
2. Bonner-Weir S., Trent D.F., Weir G.C. Partial pancreatectomy in the rat and subsequent defect in glucoseinduced insulin release. J. Clin. Invest. 1983, 71:1544-1553.
3. Brechbiel M.W. Bifunctional chelates for metal nuclides. Q. J. Nucl. Med. Mol. Imaging 2008, 52:166-173.
4. Brechbiel M.W., Gansow O.A., Atcher R.W., Schlom J., Esteban J., Simpson D., Colcher D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody Labeling Tumor-Imaging Stud. 1986, 25:2772-2781.
5. Brockmann J., Rosch F. Determination of stability constants in Y-DTPA-peptide-systems: evaluation of a radiochemical method using n. c. a. Yttrium-88. Radiochim. Acta 1999, 87:79-85.
6. Gepts W., Lecompte P.M. The pancreatic islets in diabetes. Am. J. Med. 1981, 70:105-115.
7. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J. Nucl. Med. 2009, 50:382-389.
8. Hnatowich D.J., Layne W.W., Childs R.L. The preparation and labeling of DTPA-coupled albumin. Int. J. Appl. Radiat. Isot. 1982, 33:327-332.
9. Hnatowich D.J., Layne W.W., Childs R.L., Lanteigne D., Davis M.A., Griffin T.W., Doherty P.W. Radioactive labeling of antibody: a simple and efficient method. Science 1983, 220(4597):613-615.
10. Karacay H., Brard P.Y., Sharkey R.M., et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin. Cancer Res. 2005, 11:7879-7885.
11. Körner M., Stöckli M., Waser B., Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med. 2007, 48:736-743.
12. 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J. Nucl. Med. 2008, 49:1171-1176.
13. Kwan E.P., Gaisano H.Y. Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet beta-cells. Diabetes 2005, 54:2734-2743.
14. 99mTc. Nucl. Med. Biol. 2003, 30:207-214.
15. 99mTc-labeled morpholino oligomers. Antisense Nucleic Acid Drug Dev. 2002, 12:393-398.
16. 3-conjugated morpholino oligomers. Bioconjug. Chem. 2002, 13:893-897.
17. 188Re at high labeling efficiency and specific radioactivity. Appl. Radiat. Isot. 2006, 64:971-978.
18. Liu G., Hnatowich D.J. A semiempirical model of tumor pretargeting. Bioconjug. Chem. 2008, 19:2095-2104.
19. 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation. Mol. Imaging Biol. 2009, 11:303-307.
20. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Deliv. Rev. 2008, 60:1347-1370.
21. Lu Y., Dang H., Middleton B., Zhang Z., Washburn L., Stout D.B., Campbell-Thompson M., Atkinson M.A., Phelps M., Gambhir S.S., Tian J., Kaufman D.L. Noninvasive imaging of islet grafts using positron-emission tomography. Proc. Natl. Acad. Sci. USA 2006, 103:11294-11299.
22. Magnani P., Paganelli G., Modorati G., et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J. Nucl. Med. 1996, 37:967-971.
23. Moore A., Bonner-Weir S., Weissleder R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes 2001, 50:2231-2236.
24. Pagel J.M., Hedin N., Subbiah K., et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003, 101:2340-2348.
25. Polonsky K.S., Sturis J., Bell G.I. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulindependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N. Engl. J. Med. 1996, 334:777-783.
26. Satake K., Okuyama T., Ohashi M., Shinoda T. The spectrophotometric determination of amine, amino acid and peptide with 2,4,6-tronitrobenzene 1-sulfonic acid. J. Biochem. 1960, 47:654-660.
27. Saito K., Yaginuma N., Takahashi T. Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku J. Exp. Med. 1979, 129:273-283.
28. Saudek F., Brogren C.H., Manohar S. Imaging the beta-cell mass: why and how. Rev. Diabet. Stud. 2008, 5:6-12.
29. Sharkey R.M., Cardillo T.M., Rossi E.A., et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat. Med. 2005, 11:1250-1255.
30. Souza F., Freeby M., Hultman K., et al. Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr. Med. Chem. 2006, 13:2761-2773.
31. Subbiah K., Hamlin D.K., Pagel J.M., et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J. Nucl. Med. 2003, 44:437-445.
32. Tominaga M., Maruyama H., Bolli G., et al. Simulation of the normal glucopenia-induced decline in insulin partially restores the glucagon response to glucopenia in isolated perfused pancreata of streptozotocin-diabetic rats. Endocrinology 1986, 118:886-887.
33. 99mTc radiolabeling of biomolecules. Nat. Protoc. 2006, 1:1477-1480.
34. 2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J. Nucl. Med. 2006, 47:2025-2033.
35. Yamada H., Imoto T., Fujita K., Okazaki K., Motomura M. Selective modification of aspartic acid-101 in lysozyme by carbodiimide reaction. Biochemistry 1981, 20:4836-4842.
36. Zhang Y.M., Liu N., Zhu Z.H., Rusckowski M., Hnatowich D.J. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur. J. Nucl. Med. 2000, 27:1700-1707.